MeiraGTx (NASDAQ:MGTX) Given New $30.00 Price Target at Piper Sandler

MeiraGTx (NASDAQ:MGTX) had its price target boosted by Piper Sandler from $26.00 to $30.00 in a research note released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MeiraGTx in a research report on Thursday, January 22nd. Zacks Research raised MeiraGTx from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Bank of America lifted their price objective on MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, Royal Bank Of Canada lifted their price objective on MeiraGTx from $16.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, April 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.67.

MeiraGTx Stock Performance

MeiraGTx stock opened at $10.03 on Wednesday. The stock has a fifty day moving average of $8.27 and a two-hundred day moving average of $8.16. The company has a market capitalization of $816.94 million, a price-to-earnings ratio of -7.06 and a beta of 1.27. MeiraGTx has a fifty-two week low of $4.55 and a fifty-two week high of $11.85.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.79. The business had revenue of $75.36 million during the quarter, compared to the consensus estimate of $3.87 million. MeiraGTx had a negative return on equity of 1,065.47% and a negative net margin of 140.31%. On average, analysts forecast that MeiraGTx will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of the business’s stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total transaction of $459,420.00. Following the completion of the sale, the chief executive officer owned 1,449,695 shares of the company’s stock, valued at approximately $10,742,239.95. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Richard Giroux sold 56,000 shares of the business’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $10.22, for a total value of $572,320.00. Following the sale, the chief financial officer directly owned 971,530 shares of the company’s stock, valued at approximately $9,929,036.60. This trade represents a 5.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 145,661 shares of company stock valued at $1,290,647. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On MeiraGTx

Institutional investors have recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. grew its position in MeiraGTx by 183.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 308,509 shares of the company’s stock valued at $2,453,000 after acquiring an additional 199,528 shares during the period. AMH Equity Ltd purchased a new stake in MeiraGTx during the third quarter valued at about $658,000. Virtus Investment Advisers LLC purchased a new stake in MeiraGTx during the fourth quarter valued at about $237,000. AlphaCentric Advisors LLC purchased a new stake in MeiraGTx during the fourth quarter valued at about $227,000. Finally, Hsbc Holdings PLC grew its position in MeiraGTx by 24.3% during the fourth quarter. Hsbc Holdings PLC now owns 23,792 shares of the company’s stock valued at $189,000 after acquiring an additional 4,649 shares during the period. Hedge funds and other institutional investors own 67.48% of the company’s stock.

Key Stories Impacting MeiraGTx

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: Piper Sandler raised its price target to $30 and reaffirmed an “overweight” rating — a material upside versus the current price that could support longer-term buying interest. Piper Sandler raises PT to $30
• Positive Sentiment: HC Wainwright projects MeiraGTx reaching positive EPS in FY2027 (FY2027 EPS $0.32; Q4 2027 at $2.08), suggesting a path to profitability that could re-rate the stock if execution and clinical progress stay on track.
• Neutral Sentiment: HC Wainwright issued multiple mixed estimate changes for 2026–2027 (small raises to Q3/Q4 2026 and FY2026 less negative, but modest cuts to Q1/Q2 2026). The revisions show evolving visibility but leave near-term results uncertain.
• Neutral Sentiment: Institutional ownership is high (~67%), and several funds have modestly increased stakes — this can amplify moves but also provide a stable shareholder base.
• Negative Sentiment: CFO Richard Giroux sold 56,000 shares at an average $10.22 under a pre-arranged Rule 10b5-1 plan. Insider sales can weigh on sentiment even if pre-planned; note the filing shows the transaction. SEC filing for CFO sale

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.